ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025.
Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions.
Conference Call & Webcast Details
Date: Wednesday, March 12, 2025
Time: 5:30 PM EDT
Registration: Click here to register to receive login credentials and dial-in details.
About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (nVNS) technology platform. The company focuses on commercializing medical devices for managing and treating specific medical conditions, as well as consumer products utilizing nVNS to enhance general well-being and human performance in the United States and select international markets.
For more information, visit www.electrocore.com.
Contact:
ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$5.73 |
| Daily Change: | 0.37 6.90 |
| Daily Volume: | 184,472 |
| Market Cap: | US$37.530M |
March 12, 2025 February 27, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
